SG/CALL/NOVO-NORDISK B/1250/0.1/19.06.26 | Market Closed - Boerse Frankfurt Warrants 03:47:49 2024-05-22 pm EDT | ||
| 1.77 EUR | -2.21% |
|
| Current month | -3.28% | ||
| 1 month | +2.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 1.77 | -2.21% |
| 24-05-21 | 1.81 | +4.62% |
| 24-05-20 | 1.73 | +2.98% |
| 24-05-17 | 1.68 | -4.00% |
| 24-05-16 | 1.75 | -2.23% |
Real-time Boerse Frankfurt Warrants
Last update May 22, 2024 at 03:47 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW7HU3 |
| ISIN | DE000SW7HU35 |
| Date issued | 2024-03-11 |
| Strike | 1,250 kr |
| Maturity | 2026-06-19 (758 Days) |
| Parity | 10 : 1 |
| Emission price | 2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.12 € |
|---|---|
| Lowest since issue | 1.45 € |
| Spread | 0.05 € |
| Spread % | 2.73% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Warrants
- Warrant
